RTA laboratuvarlari (RTALB) Fundamental Analysis
This page summarises the financial statements and the KapAI scorecard of RTA laboratuvarlari (RTALB) in the Pharmaceuticals & Healthcare sector for the 2026/6 period. Figures are compiled from the company’s reported balance sheet and income statement, in millions of Turkish lira.
Company Information
- Company: RTA laboratuvarlari
- Ticker: RTALB
- Sector: Pharmaceuticals & Healthcare
- Latest reporting period: 2026/6
KapAI Scorecard
Overall score: 3.1 / 5
- Profitability: 1.2 / 5
- Liquidity: 5.0 / 5
- Leverage: 3.7 / 5
- Efficiency: 2.4 / 5
Summary Income Statement (TRY million)
Period: 2026/6 · Compared with: 2025/6
| Item | 2026/6 | 2025/6 | Change |
|---|---|---|---|
| Revenue | 172 | 139 | +23.9% |
| Gross Profit | 38 | 50 | -24.1% |
| Operating Profit | -23 | -24 | +3.3% |
| EBITDA | 0 | 0 | — |
| Net Monetary Position Gains | 13 | 84 | -84.9% |
| Net Profit for the Period | -567 | 422 | -234.2% |
Summary Balance Sheet (TRY million)
Period: 2026/6 · Compared with: 2025/6
| Item | 2026/6 | 2025/6 | Change |
|---|---|---|---|
| Current Assets | 287 | 173 | +66.3% |
| Non-Current Assets | 2,998 | 2,055 | +45.9% |
| Total Assets | 3,285 | 2,228 | +47.5% |
| Current Liabilities | 60 | 77 | -22.5% |
| Non-Current Liabilities | 302 | 26 | +1,047.9% |
| Total Liabilities | 361 | 104 | +249.1% |